Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125043256 | 12504325 | 6 | F | 2015 | 20160926 | 20160628 | 20160929 | EXP | US-PFIZER INC-2016320211 | PFIZER | 78.00 | YR | F | Y | 59.00000 | KG | 20160929 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125043256 | 12504325 | 1 | PS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Oral | 8 MG, DAILY | D | N21812 | 22030 | 8 | MG | MODIFIED-RELEASE TABLET | |||||
| 125043256 | 12504325 | 2 | SS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Oral | 10 MG, DAILY | D | 22030 | 10 | MG | MODIFIED-RELEASE TABLET | ||||||
| 125043256 | 12504325 | 3 | C | DONEPEZIL. | DONEPEZIL | 1 | 10 MG, DAILY (ONCE A DAY) | 0 | 10 | MG | TABLET | ||||||||
| 125043256 | 12504325 | 4 | C | MYRBETRIQ | MIRABEGRON | 1 | UNK | 0 | |||||||||||
| 125043256 | 12504325 | 5 | C | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | UNK | 0 | |||||||||||
| 125043256 | 12504325 | 6 | C | ASPIRIN. | ASPIRIN | 1 | 81 MG, UNK | 0 | 81 | MG | |||||||||
| 125043256 | 12504325 | 7 | C | NEURONTIN | GABAPENTIN | 1 | 600 MG, 2X/DAY | 0 | 600 | MG | CAPSULE | BID | |||||||
| 125043256 | 12504325 | 8 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 60 MG, 1X/DAY (IN THE MORNING ) | 0 | 60 | MG | TABLET | QD | ||||||
| 125043256 | 12504325 | 9 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 10 MG, ONE OR TWO A WEEK | 0 | 10 | MG | TABLET | ||||||||
| 125043256 | 12504325 | 10 | C | DULOXETINE. | DULOXETINE | 1 | 60 MG, 1X/DAY | 0 | 60 | MG | CAPSULE | QD | |||||||
| 125043256 | 12504325 | 11 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125043256 | 12504325 | 1 | Hypertonic bladder |
| 125043256 | 12504325 | 3 | Post polio syndrome |
| 125043256 | 12504325 | 4 | Urinary incontinence |
| 125043256 | 12504325 | 5 | Gastrooesophageal reflux disease |
| 125043256 | 12504325 | 6 | Anticoagulant therapy |
| 125043256 | 12504325 | 7 | Post polio syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125043256 | 12504325 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125043256 | 12504325 | Cognitive disorder | |
| 125043256 | 12504325 | Condition aggravated | |
| 125043256 | 12504325 | Cystitis | |
| 125043256 | 12504325 | Dry mouth | |
| 125043256 | 12504325 | Femur fracture | |
| 125043256 | 12504325 | Memory impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |